SCHEMBL12393267

SCHEMBL12393267

C#C[C@@]1(c2ccc3c(N)ncnn23)O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.35
▸ HTR1A P08908 1/20 0.33
▸ HSPA5 P11021 1/20 0.33
▸ PTPN1 P18031 6/20 0.32
▸ CDC25B P30305 6/20 0.32
▸ PTPN2 P17706 2/20 0.31
▸ PTPN6 P29350 2/20 0.31
▸ PTPN11 Q06124 2/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ SSTR1 P30872 1/20 0.30
▸ SSTR2 P30874 1/20 0.30
▸ SSTR4 P31391 1/20 0.30
▸ SSTR3 P32745 1/20 0.30
▸ SSTR5 P35346 1/20 0.30
▸ GJB2 P29033 1/20 0.30
▸ BCHE P06276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18636661 1.00 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL20553048 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL29727834 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL20477154 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL12243178 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL17712276 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL27086511 0.91 PDE2A (0.35) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL31063739 0.86 PDE2A (0.37) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL12393373 0.86 PDE2A (0.37) PDE2AHTR1AHSPA5PTPN1CDC25B
SCHEMBL14039002 0.86 PDE2A (0.37) PDE2AHTR1AHSPA5PTPN1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 — — US disclosed
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-01-26 — — US disclosed
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2022-07-12 — — US disclosed
US-11344565-B2 Methods for the preparation of ribosides GILEAD SCIENCES, INC. (US) 2022-05-31 — — US disclosed
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-12-23 — — US disclosed
EP-3212175-B1 METHODS FOR THE PREPARATION OF RIBOSIDES GILEAD SCIENCES INC (US) 2021-11-24 — — EP disclosed
US-11007208-B2 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2021-05-18 — — US disclosed
US-20210061806-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2021-03-04 — — US disclosed
US-20200352967-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2020-11-12 — — US disclosed
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. (US) 2020-06-30 — — US disclosed
US-8853171-B2 1′-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2014-10-07 — — US disclosed
US-8853171-B2 1′-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2014-10-07 — — US disclosed
US-20130034521-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2013-02-07 — — US disclosed
US-20130034521-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2013-02-07 — — US disclosed
US-8318682-B2 1′substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2012-11-27 — — US disclosed
US-8318682-B2 1′substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2012-11-27 — — US disclosed
US-8008264-B2 1′-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-08-30 — — US disclosed
US-8008264-B2 1′-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-08-30 — — US disclosed
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-01-28 — — US disclosed
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061806-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-10695361-B2 Methods for treating arenaviridae and coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-11007208-B2 Methods for treating arenaviridae and coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20130034521-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, MTAP, SLC29A1 PDE2A 2899/4885HTR1A 588/4885HSPA5 2596/4885
US-11344565-B2 Methods for the preparation of ribosides RUVBL2, RUVBL1, EIF2AK2 PDE2A 4326/4885HTR1A 4710/4885HSPA5 1453/4885
US-11382926-B2 Methods for treating Arenaviridae and Coronaviridae virus infections ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 PDE2A 1863/4885HTR1A 2570/4885HSPA5 4656/4885
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, MTAP, SLC29A1 PDE2A 2899/4885HTR1A 588/4885HSPA5 2596/4885
US-20210393659-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20200352967-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 PDE2A 3746/4885HTR1A 2011/4885HSPA5 3890/4885
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS PNP, ACE, ACE2 PDE2A 3717/4885HTR1A 1956/4885HSPA5 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback